JR8603

JR8603 is a small molecule tumor-targeted peptide-drug conjugate (PDC) developed by JiaRay Therapeutics for the treatment of advanced solid tumors. It is designed to selectively target and deliver cytotoxic agents to tumor cells, thereby increasing antitumor efficacy while minimizing off-target toxicity. Preclinical studies have demonstrated robust anticancer activity in various rodent models after intravenous administration, with favorable pharmacokinetic and metabolic stability profiles. The drug has shown good solubility and safety in animal toxicology studies. Clinical development is focused on patients with advanced or metastatic solid tumors who have progressed after standard therapies, including specific expansion cohorts for gastric/EGJ cancer and colorectal cancer. Patient selection may involve prescreening for legumain protein expression as a biomarker[1][2][4][5].